Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2026)

Rocket Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $2.5 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $2.5 million, down 19.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 million (down 19.45% YoY), and the FY2025 annual result was $2.6 million, down 20.2% from the prior year.
• Operating Leases came in at $2.5 million for Q1 2026 at Rocket Pharmaceuticals, down from $2.6 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $3.7 million in Q1 2024 to a low of $200000.0 in Q1 2023.
• The 5-year median for Operating Leases is $2.9 million (2025), against an average of $2.4 million.
• Across the five-year window, Operating Leases sank 72.18% in 2023 and surged 1757.0% in 2024, its largest moves.
• Rocket Pharmaceuticals' Operating Leases stood at $1.1 million in 2022, then soared by 173.25% to $3.0 million in 2023, then rose by 9.59% to $3.3 million in 2024, then decreased by 20.2% to $2.6 million in 2025, then declined by 4.12% to $2.5 million in 2026.
• The last three Operating Leases figures came in at $2.5 million (Q1 2026), $2.6 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.